Cost sharing and the initiation of drug therapy for the chronically ill

Archives of Internal Medicine

Volumn 169, Issue 8, 2009, Pages 740-748

  Solomon, Matthew D ^a,b   Goldman, Dana P ^b   Joyce, Geoffrey F ^b   Escarce, José J ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA 1 ANTITRYPSIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; INSULIN; METFORMIN; NICOTINIC ACID; POTASSIUM SPARING DIURETIC AGENT; STATIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

AGED; ARTICLE; CHRONIC DISEASE; CHRONIC PATIENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SURVIVAL; VASCULAR DISEASE; COST; MULTIVARIATE ANALYSIS; TIME;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COHORT STUDIES; COST SHARING; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 65649127791     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.62     Document Type: Article

References (22)

1. Smith C, Cowan C, Heffler S, Caitlin A. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff (Millwood). 2006; 25(1):186-196.
2. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceu- tical and other medical utilization. Med Care. 2001;39(12):1293-1304.
3. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
4. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
5. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
6. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359.
7. Mueller C, Schur C, O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Am J Public Health. 1997;87(10):1626-1629.
8. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting an- tihypertensive drug therapy in a Medicaid population. Med Care. 1994;32(3): 214-226.
9. Andersson F, Cline C, Ryden-Bergsten T, Erhardt L. Angiotensin converting en- zyme (ACE) inhibitors and heart failure: the consequences of underprescribing. Pharmacoeconomics. 1999;15(6):535-550.
10. Franklin SS, Jacobs MJ, Wong ND, Italien GJ, Lapuerta P. Predominance of iso- lated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001;37(3):869-874.
11. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia man- agement in patients with type 2 diabetes. Am J Med. 2002;112(8):603-609.
12. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adults population: results from the Third National Health and Nutrition Examination Sur- vey, 1988-1991. Hypertension. 1995;25(3):305-313.
13. Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treat- ment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26(1):60-69.
14. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4): 518-524.
15. Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20(6):267-276.
16. Kane NM. Pharmaceutical cost containment and innovation in the United States. Health Policy. 1997;41(suppl):S71-S89.
17. Lipton HL, Gross DJ, Stebbins MR, Syed LH. Managing the pharmacy benefit in Medicare HMOs: what do we really know? Health Aff (Millwood). 2000;19(2): 42-58.
18. Hong SH, Shepherd MD. Outpatient prescription drug use by children enrolled in five drug benefit plans. Clin Ther. 1996;18(3):528-545.
19. Smith DG, Kirking DM. Impact of consumer fees on drug utilization. Pharmacoeconomics. 1992;2(4):335-342.
20. Harris BL, Stergachis A, Reid LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28(10):907-917.
21. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increas- ing patient prescription drug cost sharing on therapeutic classes of drugs re- ceived and on the health status of elderly HMO members. Health Serv Res. 1997; 32(1):103-122.
22. Safran DG, Neuman P, Schoen C, Kitchman MS, Wilson IB, Cooper B, Li A, Chang in the United States. Diabetes Res Clin Pract. 2005;70 (3):263-269.